Parasitic central nervous system infections in immunocompromised hosts: Malaria, microsporidiosis, leishmaniasis, and African trypanosomiasis

Clinical Infectious Diseases

Volumn 42, Issue 1, 2006, Pages 115-125

  Walker, Melanie ^a   Kublin, James G ^b   Zunt, Joseph B ^a,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTICONVULSIVE AGENT; ANTIMALARIAL AGENT; ANTIRETROVIRUS AGENT; ARTEMISIN DERIVATIVE; CHLOROQUINE; DEXAMETHASONE; DOXYCYCLINE; EFLORNITHINE; MEFLOQUINE; MELARSOPROL; MILTEFOSINE; PENTAMIDINE; PREDNISONE; QUINIDINE; QUININE; STIBOGLUCONATE SODIUM; SURAMIN;

AFRICAN TRYPANOSOMIASIS; BONE MARROW TRANSPLANTATION; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNOFLUORESCENCE TEST; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INFECTION SENSITIVITY; LEISHMANIASIS; MALARIA; MICROSPORIDIOSIS; OPPORTUNISTIC INFECTION; ORGAN TRANSPLANTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; SERODIAGNOSIS;

BRAIN DISEASES; CENTRAL NERVOUS SYSTEM PARASITIC INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; LEISHMANIASIS; MALARIA, CEREBRAL; MICROSPORIDIOSIS; TRYPANOSOMIASIS, AFRICAN;

EID: 29244455032     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/498510     Document Type: Review

References (156)

1. Walker M, Zunt JR. Parasitic central nervous system infections in immunocompromised hosts. Clin Infect Dis 2005; 40:1005-15.
2. Harms G, Feldmeier H. HIV infection and tropical parasitic diseases: deleterious interactions in both directions? Trop Med Int Health 2002; 7:479-88.
3. Greenberg AE, Nsa W, Ryder RW, et al. Plasmodium falciparum malaria and perinatally acquired human immunodeficiency virus type 1 infection in Kinshasa, Zaire: a prospective, longitudinal cohort study of 587 children. N Engl J Med 1991; 325:105-9.
4. Colebunders R, Bahwe Y, Nekwei W, et al. Incidence of malaria and efficacy of oral quinine in patients recently infected with human immunodeficiency virus in Kinshasa, Zaire. J Infect 1990; 21:167-73.
5. Atzori C, Bruno A, Chichino G, et al. HIV-1 and parasitic infections in rural Tanzania. Ann Trop Med Parasitol 1993; 87:585-93.
6. Drugs for parasitic infections. The medical letter on drugs and therapeutics. New Rochelle, NY: Medical Letter, 2004:1-12.
7. Bryce J, Boschi-Pinto C, Shibuya K, Black RE. World Health Organization estimates of the causes of death in children. Lancet 2005; 365:1147-52.
8. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI. The global distribution of clinical episodes of Plasmodium faldparum malaria. Nature 2005; 434:214-7.
9. Wernsdorfer G, Wernsdorfer WH. Malaria at the turn from the 2nd to the 3rd millenium. Wien Klin Wochenschr 2003; 115(Suppl. 3): 2-9.
10. Greenwood B, Mutabingwa T. Malaria in 2002. Nature 2002; 415: 670-2.
11. Muller O, Moser R. The clinical and parasitological presentation of Plasmodium falciparum malaria in Uganda is unaffected by HIV-1 infection. Trans R Soc Trop Med Hyg 1990; 84:336-8.
12. Nguyen-Dinh P, Greenberg AE, Mann JM, et al. Absence of association between Plasmodium falciparum malaria and human immunodeficiency virus infection in children in Kinshasa, Zaire. Bull World Health Organ 1987; 65:607-13.
13. Steketee RW, Wirima JJ, Bloland PB, et al. Impairment of a pregnant woman's acquired ability to limit Plasmodium falciparum by infection with human immunodeficiency virus type-1. Am J Trop Med Hyg 1996; 55:42-9.
14. Chirenda J, Siziya S, Tshimanga M. Association of HIV infection with the development of severe and complicated malaria cases at a rural hospital in Zimbabwe. Cent Afr J Med 2000; 46:5-9.
15. Simooya OO, Mwendapole RM, Siziya S, Fleming AF. Relation between falciparum malaria and HIV seropositivity in Ndola, Zambia. BMJ 1988; 297:30-1.
16. Leaver RJ, Haile Z, Watters DA. HIV and cerebral malaria. Trans R Soc Trop Med Hyg 1990; 84:201.
17. Grimwade K, French N, Mbatha DD, Zungu DD, Dedicoat M, Gilks CF. HIV infection as a cofactor for severe falciparum malaria in adults living in a region of unstable malaria transmission in South Africa. AIDS 2004; 18:547-54.
18. Grimwade K, French N, Mbatha DD, Zungu DD, Dedicoat M, Gilks CF. Childhood malaria in a region of unstable transmission and high human immunodeficiency virus prevalence. Pediatr Infect Dis J 2003; 22:1057-63.
19. van Eijk AM, Ayisi JG, ter Kuile FO, et al. Human immunodeficiency virus seropositivity and malaria as risk factors for third-trimester anemia in asymptomatic pregnant women in western Kenya. Am J Trop Med Hyg 2001; 65:623-30.
20. Verhoeff FH, Brabin BJ, Chimsuku L, Kazembe P, Broadhead RL. Malaria in pregnancy and its consequences for the infant in rural Malawi. Ann Trop Med Parasitol 1999; 93(Suppl 1):S25-33.
21. Whitworth J, Morgan D, Quigley M, et al. Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort study. Lancet 2000; 356: 1051-6.
22. Francesconi P, Fabiani M, Dente MG, et al. HIV, malaria parasites, and acute febrile episodes in Ugandan adults: a case-control study. AIDS 2001; 15:2445-50.
23. French N, Nakiyingi J, Lugada E, Watera C, Whitworth JA, Gilks CF. Increasing rates of malarial fever with deteriorating immune status in HIV-1-infected Ugandan adults. AIDS 2001; 15:899-906.
24. Hoffman IF, Jere CS, Taylor TE, et al. The effect of Plasmodium falciparum malaria on HIV-1 RNA blood plasma concentration. AIDS 1999; 13:487-94.
25. Kublin JG, Patnaik P, Jere CS, et al. Effect of Plasmodium falciparum malaria on concentration of HIV-1 RNA in the blood of adults in rural Malawi: a prospective cohort study. Lancet 2005; 365:233-40.
26. Bentwich Z, Kalinkovich A, Weisman Z. Immune activation is a dominant factor in the pathogenesis of African AIDS. Immunol Today 1995; 16:187-91.
27. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921-9.
28. Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, Ellner J. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med 1995; 151:129-35.
29. Salutari P, Sica S, Chiusolo P, et al. Plasmodium vivax malaria after autologous bone marrow transplantation: an unusual complication. Bone Marrow Transplant 1996; 18:805-6.
30. Chiche L, Lesage A, Duhamel C, et al. Posttransplant malaria: first case of transmission of Plasmodium falciparum from a white multiorgan donor to four recipients. Transplantation 2003; 75:166-8.
31. Chadee DD, Tilluckdharry CC, Maharaj P, Sinanan C. Reactivation of Plasmodium malariae infection in a Trinidadian man after neurosurgery. N Engl J Med 2000; 342:1924.
32. Cranfield MR, Graczyk TK, Beall FB, Ialeggio DM, Shaw ML, Skjoldager ML. Subclinical avian malaria infections in African black-footed penguins (Spheniscus demersus) and induction of parasite recrudescence. J Wildl Dis 1994; 30:372-6.
33. Ng CK, Mak AY, Au TS, Au TC, Lai ST, Lai JY. Plasmodium infection unmasked by corticosteroid therapy. Hong Kong Med J 1997; 3: 328-30.
34. White NJ, Looareesuwan S, Phillips IA, et al. Single dose phenobarbitone prevents convulsions in cerebral malaria. Lancet 1988; 2:64-6.
35. Newton CRJC, Hien TT, White NJ. Cerebral malaria. J Neurol Neurosurg Psychiatry 2000; 69:433-41.
36. Warrell DA. Cerebral malaria: clinical features, pathophysiology and treatment. Ann Trop Med Parasitol 1997; 91:875-84.
37. Newton CR, Hien TT, White N. Cerebral malaria. J Neurol Neurosurg Psychiatry 2000; 69:433-41.
38. Newton CR, Crawley J, Sowumni A, et al. Intracranial hypertension in Africans with cerebral malaria. Arch Dis Child 1997; 76:219-26.
39. Nguyen TH, Day NP, Ly VC, et al. Post-malaria neurological syndrome. Lancet 1996; 348:917-21.
40. Mohsen AH, McKendrick MW, Schmid ML, Green ST, Hadjivassiliou M, Romanowski C. Postmalaria neurological syndrome: a case of acute disseminated encephalomyelitis? J Neurol Neurosurg Psychiatry 2000; 68:388-9.
41. Goodgame RW. AIDS in Uganda: clinical and social features. N Engl J Med 1990; 323:383-9.
42. AIDS in Africa. N Engl J Med 1991; 324:847-8.
43. MacPherson GG, Warrell MJ, White NJ, Looareesuwan S, Warrell DA. Human cerebral malaria: a quantitative ultrastructural analysis of parasitized erythrocyte sequestration. Am J Pathol 1985; 119:385-401.
44. Turner G. Cerebral malaria. Brain Pathol 1997; 7:569-82.
45. Medana IM, Day NP, Hien TT, et al. Axonal injury in cerebral malaria. Am J Pathol 2002; 160:655-66.
46. Gitau EN, Newton CR. Review article: blood-brain barrier in falciparum malaria. Trop Med Int Health 2005; 10:285-92.
47. Kodisinghe HM, Perera KL, Premawansa S, Naotunne T, Wickramasinghe AR, Mendis KN. The ParaSight-F dipstick test as a routine diagnostic tool for malaria in Sri Lanka. Trans R Soc Trop Med Hyg 1997; 91:398-402.
48. Warrell DA, Looareesuwan S, Warrell MJ, et al. Dexamethasone proves deleterious in cerebral malaria: a double-blind trial in 100 comatose patients. N Engl J Med 1982; 306:313-9.
49. Looareesuwan S, Warrell DA, White NJ, et al. Do patients with cerebral malaria have cerebral oedema? A computed tomography study. Lancet 1983; 1:434-7.
50. Patankar TF, Karnad DR, Shetty PG, Desai AP, Prasad SR. Adult cerebral malaria: prognostic importance of imaging findings and correlation with postmortem findings. Radiology 2002; 224:811-6.
51. Looareesuwan S, Wilairatana P, Krishna S, et al. Magnetic resonance imaging of the brain in patients with cerebral malaria. Clin Infect Dis 1995; 21:300-9.
52. Cordoliani YS, Sarrazin JL, Felten D, Caumes E, Leveque C, Fisch A. MR of cerebral malaria. AJNR Am J Neuroradiol 1998; 19:871-4.
53. Sakai O, Barest GD. Diffusion-weighted imaging of cerebral malaria. J Neuroimaging 2005; 15:278-80.
54. Tran TH, Day NP, Nguyen HP, et al. A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria. N Engl J Med 1996; 335:76-83.
55. Management of severe malaria: a practical handbook. Geneva: World Health Organization, 2005.
56. Hoffman SL, Rustama D, Punjabi NH, et al. High-dose dexamethasone in quinine-treated patients with cerebral malaria: a double-blind, placebo-controlled, randomised controlled trial. Lancet 1988; 158: 325-31.
57. Meremikwu M, Marson AG. Routine anticonvulsants for treating cerebral malaria. Cochrane Database Syst Rev 2002:CD002152.
58. Molyneux ME, Taylor TE, Wirima JJ, Borgstein A. Clinical features and prognostic indicators in paediatric cerebral malaria: a study of 131 comatose Malawian children. Q J Med 1989; 71:441-59.
59. Patankar TF, Karnad DR, Shetty PG, Desai AP, Prasad SR. Adult cerebral malaria: prognostic importance of imaging findings and correlation with postmortem findings. Radiology 2002; 224:811-6.
60. Holding PA, Stevenson J, Peshu N, et al. Cognitive sequelae of severe malaria with impaired consciousness. Trans R Soc Trop Med Hyg 1999; 93:529-34.
61. Didier ES, Stovall ME, Green LC, Brindley PJ, Sestak K, Didier PJ. Epidemiology of microsporidiosis: sources and modes of transmission. Vet Parasitol 2004; 126:145-66.
62. Weiss LM. Microsporidia: emerging pathogenic protists. Acta Trop 2001; 78:89-102.
63. Franzen C, Muller A. Microsporidiosis: human diseases and diagnosis. Microbes Infect 2001; 3:389-400.
64. Hutin YJ, Sombardier MN, Liguory O, et al. Risk factors for intestinal microsporidiosis in patients with human immunodeficiency virus infection: a case-control study. J Infect Dis 1998; 178:904-7.
65. Weber R, Deplazes P, Flepp M, et al. Cerebral microsporidiosis due to Encephalitozoon cuniculi in a patient with human immunodeficiency virus infection. N Engl J Med 1997; 336:474-8.
66. Schwartz DA, Visvesvara G, Weber R, Bryan RT. Male genital tract microsporidiosis and AIDS: prostatic abscess due to Encephalitozoon hellem. J Eukaryot Microbiol 1994; 41:61S.
67. Bigliardi E, Sacchi L. Cell biology and invasion of the microsporidia. Microbes Infect 2001; 3:373-9.
68. Maggi P, Larocca AM, Quarto M, et al. Effect of antiretroviral therapy on cryptosporidiosis and microsporidiosis in patients infected with human immunodeficiency virus type 1. Eur J Clin Microbiol Infect Dis 2000; 19:213-7.
69. Oldfield EC 3rd. Evaluation of chronic diarrhea in patients with human immunodeficiency virus infection. Rev Gastroenterol Disord 2002; 2:176-88.
70. Chu P, West AB. Encephalitozoon (Septata) intestinalis: cytologic, histologic, and electron microscopic features of a systemic intestinal pathogen. Am J Clin Pathol 1996; 106:606-14.
71. Carlson JR, Li L, Helton CL, et al. Disseminated microsporidiosis in a pancreas/kidney transplant recipient. Arch Pathol Lab Med 2004; 128:e41-3.
72. Rabodonirina M, Cotte L, Radenne S, Besada E, Trepo C. Microsporidiosis and transplantation: a retrospective study of 23 cases. J Eukaryot Microbiol 2003; 50(Suppl):583.
73. Teachey DT, Russo P, Orenstein JM, Didier ES, Bowers C, Bunin N. Pulmonary infection with microsporidia after allogeneic bone marrow transplantation. Bone Marrow Transplant 2004; 33:299-302.
74. Mohindra AR, Lee MW, Visvesvara G, et al. Disseminated microsporidiosis in a renal transplant recipient. Transpl Infect Dis 2002; 4: 102-7.
75. Bergquist NR, Stintzing G, Smedman L, Waller T, Andersson T. Diagnosis of encephalitozoonosis in man by serological tests. Br Med J (Clin Res Ed) 1984; 288:902.
76. Matsubayashi H, Koike T, Mikata I, Takei H, Hagiwara S. A case of Encephalitozoon-like body infection in man. AMA Arch Pathol 1959; 67:181-7.
77. Yachnis AT, Berg J, Martinez-Salazar A, et al. Disseminated microsporidiosis especially infecting the brain, heart, and kidneys: report of a newly recognized pansporoblastic species in two symptomatic AIDS patients. Am J Clin Pathol 1996; 106:535-43.
78. Franzen C, Muller A, Hartmann P, Salzberger B. Quantitation of microsporidia in cultured cells by flow cytometry. Cytometry A 2004; 60A:107-14.
79. Weiss LM, Vossbrinck CR. Microsporidiosis: molecular and diagnostic aspects. Adv Parasitol 1998; 40:351-95.
80. Bryan RT, Weber R. Microsporidia: emerging pathogens in immunodeficient persons. Arch Pathol Lab Med 1993; 117:1243-5.
81. Weber R, Bryan RT, Schwartz DA, Owen RL. Human microsporidial infections. Clin Microbiol Rev 1994; 7:426-61.
82. Reetz J, Wiedemann M, Aue A, et al. Disseminated lethal Encephalitozoon cuniculi (genotype III) infections in cotton-top tamarins (Oedipomidas oedipus): a case report. Parasitol Int 2004; 53:29-34.
83. Menotti J, Cassinat B, Sarfati C, Liguory O, Derouin F, Molina JM. Development of a real-time PCR assay for quantitative detection of Encephalitozoon intestinalis DNA. J Clin Microbiol 2003; 41:1410-3.
84. Cheney SA, Lafranchi-Tristem NJ, Canning EU. Serological differentiation of microsporidia with special reference to Trachipleistophora hominis. Parasite 2001; 8:91-7.
85. Franzen C. Microsporidia: how can they invade other cells? Trends Parasitol 2004; 20:275-9.
86. Tosoni A, Nebuloni M, Ferri A, et al. Disseminated microsporidiosis caused by Encephalitozoon cuniculi III (dog type) in an Italian AIDS patient: a retrospective study. Mod Pathol 2002; 15:577-83.
87. Berg J, Diaz LE, Bender BS. Microsporidia in humans. Ann Intern Med 1996; 125:522-3.
88. Mertens RB, Didier ES, Fishbein MC, Bertucci DC, Rogers LB, Orenstein JM. Encephalitozoon cuniculi microsporidiosis: infection of the brain, heart, kidneys, trachea, adrenal glands, and urinary bladder in a patient with AIDS. Mod Pathol 1997; 10:68-77.
89. Molina JM, Oksenhendler E, Beauvais B, et al. Disseminated microsporidiosis due to Septata intestinalis in patients with AIDS: clinical features and response to albendazole therapy. J Infect Dis 1995; 171: 245-9.
90. Lafaurie M, Sarfati C, Menotti J, Molina JM. Remission of disseminated infection caused by Encephalocytozoon intestinalis with highly active antiretroviral therapy. AIDS 2003; 17:640-1.
91. Cruz I, Morales MA, Noguer I, Rodriguez A, Alvar J. Leishmania in discarded syringes from intravenous drug users. Lancet 2002; 359: 1124-5.
92. Leishmaniasis. Geneva: World Health Organization, 2005.
93. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 2004; 27:305-18.
94. Alvar J, Canavate C, Gutierrez-Solar B, et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev 1997; 10:298-319.
95. Olivier M, Badaro R, Medrano FJ, Moreno J. The pathogenesis of Leishmania/HIV coinfection: cellular and immunological mechanisms. Ann Trop Med Parasitol 2003; 97(Suppl 1):79-98.
96. Fernandez-Guerrero ML, Robles P, Rivas P, Mojer F, Muniz G, de Gorgolas M. Visceral leishmaniasis in immunocompromised patients with and without AIDS: a comparison of clinical features and prognosis. Acta Trop 2004; 90:11-6.
97. de La Rosa R, Pineda JA, Delgado J, et al. Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy. J CHn Microbiol 2002; 40:762-7.
98. Bernier R, Barbeau B, Tremblay MJ, Olivier M. The lipophosphoglycan of Leishmania donovani up-regulates HIV-1 transcription in T cells through the nuclear factor-kappaB elements. J Immunol 1998; 160:2881-8.
99. Ferreira MS, Borges AS. Some aspects of protozoan infections in immunocompromised patients: a review. Mem Inst Oswaldo Cruz 2002; 97:443-57.
100. Frapier JM, Abraham B, Dereure J, Albat B. Fatal visceral leishmaniasis in a heart transplant recipient. J Heart Lung Transplant 2001; 20: 912-3.
101. Gontijo CM, Pacheco RS, Orefice F, Lasmar E, Silva ES, Melo MN. Concurrent cutaneous, visceral and ocular leishmaniasis caused by Leishmania (Viannia) braziliensis in a kidney transplant patient. Mem Inst Oswaldo Cruz 2002; 97:751-3.
102. Hernandez-Perez J, Yebra-Bango M, Jimenez-Martinez E, et al. Visceral leishmaniasis (kala-azar) in solid organ transplantation: report of five cases and review. Clin Infect Dis 1999; 29:918-21.
103. Moroni G, Bossi L. Don't forget visceral leishmaniasis in transplant patients. Nephrol Dial Transplant 1995; 10:563-4.
104. Sirvent-von Bueltzingsloewen A, Marty P, Rosenthal E, et al. Visceral leishmaniasis: a new opportunistic infection in hematopoietic stem cell-transplanted patients. Bone Marrow Transplant 2004; 33:667-8.
105. Morales MA, Cruz I, Rubio JM, et al. Relapses versus reinfections in patients coinfected with Leishmania infantum and human immunodeficiency virus type 1. J Infect Dis 2002; 185:1533-7.
106. Berenguer J, Gomez-Campdera F, Padilla B, et al. Visceral leishmaniasis (kala-azar) in transplant recipients: case report and review. Transplantation 1998; 65:1401-4.
107. Silveira FT, Lainson R, Corbett CE. Clinical and immunopathological spectrum of American cutaneous leishmaniasis with special reference to the disease in Amazonian Brazil: a review. Mem Inst Oswaldo Cruz 2004; 99:239-51.
108. Couppie P, Clyti E, Sobesky M, et al. Comparative study of cutaneous leishmaniasis in human immunodeficiency virus (HIV)-infected patients and non-HIV-infected patients in French Guiana. Br J Dermatol 2004; 151:1165-71.
109. Rosenthal E, Marty P, del Giudice P, et al. HIV and Leishmania coinfection: a review of 91 cases with focus on atypical locations of Leishmania. Clin Infect Dis 2000; 31:1093-5.
110. Kubar J, Marty P, Lelievre A, et al. Visceral leishmaniosis in HIV-positive patients: primary infection, reactivation and latent infection-impact of the CD4+ T-lymphocyte counts. AIDS 1998; 12: 2147-53.
111. Albrecht H, Sobottka I, Emminger C, et al. Visceral leishmaniasis emerging as an important opportunistic infection in HIV-infected persons living in areas nonendemic for Leishmania donovani. Arch Pathol Lab Med 1996; 120:189-98.
112. Asensi V, Tricas L, Meana A, et al. Visceral leishmaniasis and other severe infections in an adult patient with p47-phox-deficient chronic granulomatous disease. Infection 2000; 28:171-4.
113. Hashim FA, Ahmed AE, el Hassan M, et al. Neurologic changes in visceral leishmaniasis. Am J Trop Med Hyg 1995; 52:149-54.
114. Karak B, Garg RK, Misra S, Sharma AM. Neurological manifestations in a patient with visceral leishmaniasis. Postgrad Med J 1998; 74: 423-5.
115. Chunge CN, Gachihi G, Muigai R. Is neurological involvement possible in visceral leishmaniasis in Kenya. Trans R Soc Trop Med Hyg 1985; 79:872.
116. Mustafa D. Neurological disturbances in visceral leishmaniasis. J Trop Med Hyg 1965; 68:248-50.
117. Huna-Baron R, Warren FA, Miller W, Jacobs J, Green J, Kupersmith MJ. Mucosal leishmaniasis presenting as sinusitis and optic neuropathy. Arch Ophthalmol 2000; 118:852-4.
118. Fasanaro AM, Scoleri G, Pizza V, Gaeta GB, Fasanaro A. Guillain-Barré syndrome as presenting manifestation of visceral leishmaniasis. Lancet 1991; 338:1142.
119. Attarian S, Serratrice J, Mazodier C, Disdier P, Azulay JP, Pouget J. Guillain-Barré syndrome revealing visceral leishmaniasis in an immunocompetent woman [in French]. Rev Neurol (Paris) 2003; 159: 1046-8.
120. Medrano FJ, Hernandez-Quero J, Jimenez E, et al. Visceral leishmaniasis in HIV-1-infected individuals: a common opportunistic infection in Spain? AIDS 1992; 6:1499-503.
121. Piarroux R, Gambarelli F, Dumon H, et al. Comparison of PCR with direct examination of bone marrow aspiration, myeloculture, and serology for diagnosis of visceral leishmaniasis in immunocompromised patients. J Clin Microbiol 1994; 32:746-9.
122. Prasad LS, Sen S. Migration of Leishmania donovani amastigotes in the cerebrospinal fluid. Am J Trop Med Hyg 1996; 55:652-4.
123. Dereure J, Pratlong F, Reynes J, Basset D, Bastien P, Dedet JP. Haemoculture as a tool for diagnosing visceral leishmaniasis in HIV-negative and HIV-positive patients: interest for parasite identification. Bull World Health Organ 1998; 76:203-6.
124. Bretagne S, Durand R, Olivi M, et al. Real-time PCR as a new tool for quantifying Leishmania infantum in liver in infected mice. Clin Diagn Lab Immunol 2001; 8:828-31.
125. Singh S, Sivakumar R. Challenges and new discoveries in the treatment of leishmaniasis. J Infect Chemother 2004; 10:307-15.
126. Laguna F. Treatment of leishmaniasis in HIV-positive patients. Ann Trop Med Parasitol 2003; 97(Suppl 1):135-42.
127. Lopez-Velez R, Perez-Molina JA, Guerrero A, et al. Clinicoepidemiologic characteristics, prognostic factors, and survival analysis of patients coinfected with human immunodeficiency virus and Leishmania in an area of Madrid, Spain. Am J Trop Med Hyg 1998; 58: 436-43.
128. Calza L, Marinacci G, Manfredi R, Colangeli V, Fortunato L, Chiodo F. Pentamidine isethionate as treatment and secondary prophylaxis for disseminated cutaneous leishmaniasis during HIV infection: case report. J Chemother 2001; 13:653-7.
129. Thakur CP, Sinha GP, Pandey AK, Barat D, Sinha PK. Amphotericin B in resistant kala-azar in Bihar. Natl Med J India 1993; 6:57-60.
130. Kuzoe FA. Current situation of African trypanosomiasis. Acta Trop 1993; 54:153-62.
131. Kennedy PG. Human African trypanosomiasis of the CNS: current issues and challenges. J Clin Invest 2004; 113:496-504.
132. Noireau F, Brun-Vezinet F, Larouze B, Nzoukoudi MY, Gouteux JP. Absence of relationship between human immunodeficiency virus 1 and sleeping sickness. Trans R Soc Trop Med Hyg 1987; 81:1000.
133. Meda HA, Doua F, Laveissiere C, et al. Human immunodeficiency virus infection and human African trypanosomiasis: a case-control study in Cote d'Ivoire. Trans R Soc Trop Med Hyg 1995; 89:639-43.
134. Louis JP, Moulia-Pelat JP, Jannin J, et al. Absence of epidemiological inter-relations between HIV infection and African human trypanosomiasis in central Africa. Trop Med Parasitol 1991; 42:155.
135. Chretien JP, Smoak BL. African trypanosomiasis: changing epidemiology and consequences. Curr Infect Dis Rep 2005; 7:54-60.
136. Apted F. Clinical manifestations and diagnosis of sleeping sickness. In: Mulligan HW, ed. The African trypanosomasis. London: Allen and Unwin, 1970:661-83.
137. de Atouguia J, Kennedy PGE. Neurological aspects of human African trypanosomiasis. In: Davis LE, Kennedy PGE, eds. Infectious diseases of the nervous system. Oxford: Butterworth-Heinemann, 2000: 321-72.
138. Burri C, Nkunku S, Merolle A, Smith T, Blum J, Brun R. Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Lancet 2000; 355:1419-25.
139. Buguet A, Bisser S, Josenando T, Chapotot F, Cespuglio R. Sleep structure: a new diagnostic tool for stage determination in sleeping sickness. Acta Trop 2005; 93:107-17.
140. Control and surveillance of African trypanosomiasis. World Health Organization. World Health Organ Tech Rep Ser 1998; 881:1-113.
141. Lejon V, Reiber H, Legros D, et al. Intrathecal immune response pattern for improved diagnosis of central nervous system involvement in trypanosomiasis. J Infect Dis 2003; 187:1475-83.
142. Gill DS, Chatha DS, del Carpio-O'Donovan R. MR imaging findings in African trypansomiasis. AJNR Am J Neuroradiol 2003; 24:1383-5.
143. Nok AJ. Arsenicals (melarsoprol), pentamidine and suramin in the treatment of human African trypanosomiasis. Parasitol Res 2003; 90: 71-9.
144. Schmid C, Nkunku S, Merolle A, Vounatsou P, Burri C. Efficacy of 10-day melarsoprol schedule 2 years after treatment for late-stage gambiense sleeping sickness. Lancet 2004; 364:789-90.
145. Abel PM, Kiala G, Loa V, et al. Retaking sleeping sickness control in Angola. Trop Med Int Health 2004; 9:141-8.
146. Blum J, Nkunku S, Burri C. Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis. Trop Med Int Health 2001; 6:390-400.
147. Pepin J, Ethier L, Kazadi C, Milord F, Ryder R. The impact of human immunodeficiency virus infection on the epidemiology and treatment of Trypanosoma brucei gambiense sleeping sickness in Nioki, Zaire. Am J Trop Med Hyg 1992; 47:133-40.
148. De Clercq E. Suramin: a potent inhibitor of reverse transcriptase of RNA tumor viruses. Cancer Lett 1979; 8:9-22.
149. Dedet JP, Pratlong F. Leishmania, Trypanosoma and monoxenous trypanosomatids as emerging opportunistic agents. J Eukaryot Microbiol 2000; 47:37-9.
150. Morales P, Torres JJ, Salavert M, Peman J, Lacruz J, Sole A. Visceral leishmaniasis in lung transplantation. Transplant Proc 2003; 35: 2001-3.
151. Vithayasai P, Vithayasai V. Clinical manifestations of 174 AIDS cases in Maharaj Nakorn Chiang Mai Hospital. J Dermatol 1993; 20:389-93.
152. Cecchini A, Pricca P, Mariani P, et al. Neuro-AIDS: a multicenter neuroradiological study [in Italian]. Radiol Med (Torino) 1989; 77: 602-12.
153. Berger BJ, Fairlamb AH. Interactions between immunity and chemotherapy in the treatment of the trypanosomiases and leishmaniases. Parasitology 1992; 105(Suppl):S71-8.
154. Bonnet F, Morlat P, Chene G, et al. Causes of death among HIV-infected patients in the era of highly active antiretroviral therapy, Bordeaux, France, 1998-1999. HIV Med 2002; 3:195-9.
155. Dupouy-Camet J. New drugs for the treatment of human parasitic protozoa [in French]. Parassitologia 2004; 46:81-4.
156. Figueiro-Filho EA, Duarte G, El-Beitune P, Quintana SM, Maia TL. Visceral leishmaniasis (kala-azar) and pregnancy. Infect Dis Obstet Gynecol 2004; 12:31-40.